Show item record

dc.contributor.authorKarvellas, Constantine J.
dc.contributor.authorSpeiser, Jaime L.
dc.contributor.authorTremblay, Mélanie
dc.contributor.authorLee, William M.
dc.contributor.authorRose, Christopher
dc.date.accessioned2020-11-04T13:36:49Z
dc.date.availableNO_RESTRICTIONfr
dc.date.available2020-11-04T13:36:49Z
dc.date.issued2017-01-19
dc.identifier.urihttp://hdl.handle.net/1866/24033
dc.publisherWileyfr
dc.subjectLiver type fatty acid binding proteinfr
dc.subjectMultiorgan failurefr
dc.subjectPrognosisfr
dc.subjectALFSG indexfr
dc.titleElevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failurefr
dc.typeArticlefr
dc.contributor.affiliationUniversité de Montréal. Faculté de médecine. Département de médecinefr
dc.identifier.doi10.1002/hep.28945
dcterms.abstractBackground/Aim Acetaminophen (APAP)-induced Acute Liver Failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Hypothesis: Serum Liver-type Fatty Acid Binding Protein (FABP1) early (day 1) or late (day 3–5) levels are associated with 21-day mortality in the absence of liver transplant. Methods Serum samples from 198 APAP-ALF patients (nested case control study with 99 survivors, 99 non-survivors) were analyzed by ELISA methods and assessed with clinical data from the US Acute Liver Failure Study Group (ALFSG) Registry (1998–2014). Results APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 vs. 690.8 ng/ml, p <0.0001) and late (148.4 vs. 612.3 ng/ml, p <0.0001) compared with non-survivors. FABP1 > 350 ng/ml was associated with significantly higher risk of death at early (p=0.0004) and late (p<0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio (OR) 1.31, p=0.027) and late (log FABP1 OR 1.50, p =0.005) were associated with significantly increased 21-day mortality after adjusting for significant covariates (MELD, vasopressor use). Areas under the receiver-operating curve (AUROC) for early and late multivariable models were 0.778 and 0.907 respectively. AUROC of the King’s College Criteria (KCC) (Early: 0.552 alone, 0.711 with FABP1; Late: 0.604 alone, 0.797 with FABP1) and ALFSG prognostic index (Early: 0.686 alone, 0.766 with FABP1; Late: 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (p <0.002 for all). Conclusion In patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from non-survivors and may improve models currently used in clinical practice. Validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation.fr
dcterms.isPartOfurn:ISSN:0270-9139fr
dcterms.isPartOfurn:ISSN:1527-3350fr
dcterms.languageengfr
UdeM.ReferenceFournieParDeposant10.1002/hep.28945fr
UdeM.VersionRioxxVersion acceptée / Accepted Manuscriptfr
oaire.citationTitleHepatologyfr
oaire.citationVolume65fr
oaire.citationIssue3fr
oaire.citationStartPage938fr
oaire.citationEndPage949fr


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show item record


DSpace software [version 5.8 XMLUI], copyright © 2002-2015  DuraSpace